ReviewWorld journal of hepatology2015
Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 60 citations in OpenAlex.
- Novel Pyrazino[1,2-Viruses · 2024Article
- Revolution in the diagnosis and management of hepatitis C virus infection in current era.World journal of hepatology · 2022Article
- Spectrum of Kidney Diseases in Patients With Hepatitis C Virus Infection.American journal of clinical pathology · 2021Article
- Electronic medical record alert activation increase hepatitis C and HIV screening rates in primary care practices within a large healthcare system.Preventive medicine reports · 2020Article
- Article
- Environmental health in the biology century: Transitions from population to personalized prevention.Experimental biology and medicine (Maywood, N.J.) · 2019Review
- Depletion of MicroRNA-373 Represses the Replication of Hepatitis C Virus via Activation of Type 1 Interferon Response by Targeting IRF5.Yonsei medical journal · 2018Article
- Assessing Racial Disparities in HCV Infection and Care Outcomes in a Southern Urban Population.Journal of racial and ethnic health disparities · 2018Article
- Anti-Hepatitis C Virus Activity of Uridine Derivatives of 2-Deoxy Sugars.Molecules (Basel, Switzerland) · 2018Article
- Novel Uridine Glycoconjugates, Derivatives of 4-Aminophenyl 1-Thioglycosides, as Potential Antiviral Compounds.Molecules (Basel, Switzerland) · 2018Article
- Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma.The Journal of biological chemistry · 2017Article
- Flavonoids from Pterogyne nitens Inhibit Hepatitis C Virus Entry.Scientific reports · 2017Article
- Oxidative Stress and Immune Responses During Hepatitis C Virus Infection in Tupaia belangeri.Scientific reports · 2017Article
- Innate and Adaptive Immune Responses in Chronic HCV Infection.Current drug targets · 2017Review
- Economic study of the value of expanding HCV treatment capacity in Germany.BMJ open gastroenterology · 2017Article
- The Efficacy and Safety of Sofosbuvir-Containing Regimen in the Treatment of HCV Infection in Patients with Haemoglobinopathy.Mediterranean journal of hematology and infectious diseases · 2017Article
- Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability.Journal of leukocyte biology · 2016Article
- Geneticin Stabilizes the Open Conformation of the 5' Region of Hepatitis C Virus RNA and Inhibits Viral Replication.Antimicrobial agents and chemotherapy · 2016Article
- Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression.World journal of gastroenterology · 2016Review
- Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of individuals exposed to hepatitis C virus (HCV) establish a persistent infection, which is a leading cause of chronic liver disease, cirrhosis and hepatocellular carcinoma. Major progress has been made during the past twenty-five years in understanding the HCV life cycle and immune responses against HCV infection. Increasing evidence indicates that host genetic factors can significantly influence the outcome of HCV infection and the response to interferon alpha-based antiviral therapy. The arrival of highly effective and convenient treatment regimens for patients chronically infected with HCV has improved prospects for the eradication of HCV worldwide. Clinical trials are evaluating the best anti-viral drug combination, treatment doses and duration. The new treatments are better-tolerated and have shown success rates of more than 95%. However, the recent breakthrough in HCV treatment raises new questions and challenges, including the identification of HCV-infected patients and to link them to appropriate health care, the high pricing of HCV drugs, the emergence of drug resistance or naturally occurring polymorphism in HCV sequences which can compromise HCV treatment response. Finally, we still do not have a vaccine against HCV. In this concise review, we will highlight the progress made in understanding HCV infection and therapy. We will focus on the most significant unsolved problems and the key future challenges in the management of HCV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.